Acetylsalicylic Acid Is Not Associated With Improved Clinical Outcomes After Microsurgical Breast Reconstruction.

The Journal of surgical research 2023 Vol.288() p. 172-177

Liu FC, Miller TJ, Henn D, Nguyen D, Momeni A

관련 도메인

Abstract

[INTRODUCTION] Microvascular thrombosis with resultant flap loss remains a devastating complication in autologous breast reconstruction. While acetylsalicylic acid (ASA) for prevention of microvascular thrombosis is commonly administered postoperatively, clinical evidence supporting this practice remains insufficient. Here, we investigate the association of postoperative ASA administration with differences in clinical outcomes following microsurgical breast reconstruction.

[METHODS] A prospectively maintained database was queried to identify patients who had undergone microsurgical breast reconstruction. Patients were categorized based on whether they had received postoperative ASA for 30 d (Group 1) or had not received ASA (Group 2). Patient demographics, reconstructive outcomes, complications, and transfusion requirements were retrieved.

[RESULTS] One hundred thirty six patients with a mean age of 49.5 y and a mean body mass index of 28.5 kg/m who had undergone a total of 216 microsurgical breast reconstructions were included. No significant differences were noted with regard to patient demographics with the exceptions of increased rates of neoadjuvant chemotherapy and delayed reconstruction in Group 1. There were no significant differences in the rates of postoperative complications including breast hematoma, mastectomy skin flap necrosis, partial flap necrosis, seroma, and deep venous thrombosis between patients who did or did not receive ASA postoperatively. Similarly, no difference was noted regarding postoperative blood transfusion rates (Group 1: 9.9% versus Group 2: 9.1%; P = 0.78). Finally, patients in Group 1 had significantly longer hospital stays (Q1 = 4, median = 4.5, Q3 = 5).

[CONCLUSIONS] Postoperative ASA administration is not associated with improved postoperative clinical outcomes. The use of ASA routinely after autologous breast reconstruction does not appear to be a necessity in practice.

추출된 의학 개체 (NER)

유형영어 표현한국어 / 풀이UMLS CUI출처등장
해부 breast 유방 dict 7
시술 flap 피판재건술 dict 3
시술 microvascular 미세수술 dict 2
합병증 flap necrosis 괴사 dict 2
해부 blood scispacy 1
합병증 hematoma 혈종 dict 1
합병증 seroma 장액종 dict 1
약물 Acetylsalicylic Acid C0004057
aspirin
scispacy 1
약물 ASA → acetylsalicylic acid C0004057
aspirin
scispacy 1
약물 [INTRODUCTION] Microvascular thrombosis with resultant flap loss scispacy 1
약물 [RESULTS] One scispacy 1
약물 [CONCLUSIONS] scispacy 1
질환 thrombosis C0040053
Thrombosis
scispacy 1
질환 breast hematoma C0342095
Breast hematoma
scispacy 1
질환 necrosis C0027540
Necrosis
scispacy 1
기타 patients scispacy 1
기타 Patient scispacy 1
기타 skin flap scispacy 1
기타 venous scispacy 1

MeSH Terms

Humans; Middle Aged; Female; Mastectomy; Aspirin; Breast Neoplasms; Mammaplasty; Postoperative Complications; Thrombosis; Necrosis; Retrospective Studies

🔗 함께 등장하는 도메인

이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들

관련 논문